Hepatocellular Carcinogenesis: Signaling, Stromal Heterogeneity and Immune Escape
Year: 2026
Type: article
Abstract: Hepatocellular carcinoma (HCC) develops through cooperation between altered hepatocytes, chronic liver injury and a stromal and immune microenvironment. Genomic alterations and signaling abnormalities provide a rationale for treatment development, but pathway activation rarely identifies therapeutic dependence alone. This narrative review connects hepatic stellate cell states, tumor cell plasticity, genomic instability and four selected signaling pathways with antigen presentation, immune exclusion and clinical treatment evidence. Targeted searches were updated through 6 October 2026, retaining foundational work and prioritizing recent studies. Single-cell and spatial analyses reveal that stellate cells and cancer-associated fibroblasts can exert opposing effects according to their state and location. Similarly, CTNNB1-associated signaling can favor immune exclusion, but mutation status does not fully capture immune context or establish universal resistance to checkpoint combinations. Intratumoral dendritic cell and lymphocyte organization, suppressive myeloid niches and humoral responses provide complementary explanations of treatment heterogeneity. Randomized trials support selected antiangiogenic and checkpoint combinations in unresectable HCC, while negative trials and updated adjuvant results demonstrate the limits of extrapolating biological rationale across regimens and disease stages. The synthesis distinguishes experimental causality, patient-level association and clinically validated benefit. Translation requires compartment-specific target assessment, representative sampling and prospective biomarker evaluation within a defined treatment setting, alongside assessment of liver reserve.
Source: Medical Sciences
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: hepatocellular carcinoma, hepatocarcinogenesis, tumor microenvironment, hepatic stellate cells, cancer-associated fibroblasts, immune evasion, immune exclusion, genomic instability, tumor plasticity, antigen presentation, dendritic cells, immune checkpoint inhibitors, anti-angiogenic therapy, adjuvant therapy, liver function reserve, biomarkers, stromal heterogeneity
Open Access status: gold
Estimated APC paid: $1,689
OpenAlex ID: W7223110345
